UBS AM
CUE icon

UBS AM’s Cue Biopharma CUE Stock Holding History

UBS AM’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-334
Closed -$246K – 2493
2020
Q2 		$246K Buy
+334
New +$242K ﹤0.01% 2338

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

UBS AM's CUE Position: Q3 2020 in Review

UBS AM sold out of Cue Biopharma (CUE) in Q3 2020, closing a stake of 334 shares — an estimated $246K sold.

UBS AM first reported a position in CUE in Q2 2020 and held it in 1 quarter. The position peaked at $246K in Q2 2020. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

  • UBS AM reported no remaining Cue Biopharma position as of Q3 2020 after selling out during the quarter.
  • UBS AM sold 334 Cue Biopharma shares in Q3 2020, an estimated $246K.
  • UBS AM first reported a position in Cue Biopharma in Q2 2020 and held it in 1 quarter.
  • UBS AM's Cue Biopharma position peaked at $246K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on UBS AM's 13F filing for Q3 2020, filed 13 Nov 2020.